

Table of contents

Abstract	VII
Zusammenfassung/ Abstract in German	IX
1 Introduction	1
1.1 Drug discovery and development	2
1.2 The endocannabinoid system.....	4
1.2.1 Cannabinoid receptors and G protein-coupled receptors	8
1.3 Coumarins as synthetic cannabinoid ligands	10
1.3.1 Coumarin synthesis	14
1.4 Monoacylglycerol lipase.....	16
2 Aim and outline	19
3 Results and discussion	21
3.1 Synthetic work on coumarin-based cannabinoids	21
3.1.1 Synthesis of salicylic aldehydes	21
3.1.2 Synthesis of cinnamaldehydes.....	29
3.1.3 Synthesis of 7-alkoxy-3-benzylcoumarins	29
3.1.4 Synthesis of 7-dialkylamino-3-benzylcoumarins	32
3.1.5 Synthesis of 7-(1,1-dimethylalkyl)-3-benzylcoumarins.....	34
3.1.6 Synthesis of 3-benzylcoumarins.....	35
3.1.7 Synthesis of 3-alkylcoumarins	37
3.2 Pharmacological evaluation of synthetic cannabinoids.....	39
3.2.1 Radioligand binding assays	39
3.2.2 Results of competitive radioligand binding studies	41
3.2.3 Functional properties	49
3.2.4 Docking studies and Structure-activity-relationships.....	51
3.2.5 ADME and physicochemical properties.....	59
3.3 Synthesis and evaluation of MAGL inhibitors	64
3.3.1 Syntheses of benzoic acid building blocks.....	67
3.3.2 Synthetic work related to the <i>trans</i> -(2,3)-dimethylpiperazine building blocks	68
3.3.3 Syntheses of final MAGL inhibitors	75
3.3.4 Pharmacological evaluation	77
4 Conclusion and future prospects	89
5 Experimental part	95
5.1 Synthetic work on coumarin-based cannabinoids	95
5.1.1 General remarks chemistry.....	95
5.1.2 Analytics and equipment	95
5.1.3 General procedures.....	99
5.1.4 Synthesis and characterisation of salicylic aldehydes.....	102

5.1.5	Synthesis and characterisation of cinnamaldehydes	129
5.1.6	Synthesis and characterisation of 3-benzyl-7-alkoxycoumarins	131
5.1.7	Synthesis and characterisation of 3-benzyl-7-dialkylaminocoumarins.....	170
5.1.8	Synthesis and characterisation of 3-benzyl-7-(1,1-dimethyl)alkylcoumarins..	184
5.1.9	Synthesis and characterisations of 3-benzylcoumarins	210
5.1.10	Synthesis and characterisation of 3-alkylcoumarins	220
5.2	Pharmacological evaluation of synthetic cannabinoids	243
5.2.1	General remarks biology	243
5.2.2	Methods	243
5.3	Synthesis and evaluation of MAGL inhibitors	248
5.3.1	General remarks chemistry.....	248
5.3.2	Analytics and equipment	248
5.3.3	General procedures.....	250
5.3.4	Synthesis and characterisation of carboxylic part	251
5.3.5	Synthesis and characterization of trans-(2,3)-dimethylpiperazine part.....	255
5.3.6	Synthesis and characterization of final MAGL inhibitors.....	258
5.3.7	Chemical biology methods	265
6	Appendix.....	269
6.1	Synthesis strategy dialkylamino moiety	269
6.2	Synthesis strategy dimethylalkyl moiety	269
6.3	Dialkylamino coumarins.....	271
6.4	Radioligand binding assay	274
6.5	Functional properties	294
6.6	Metabolic stability	295
6.7	List of Abbreviations	297
6.8	Crystallographic data	300
6.9	Curriculum Vitae	326
7	References.....	330
8	Acknowledgments	343